BioSpace News Archive

According to Vision Research Reports, the Medical Device Regulatory Affairs market size is expected to hit around US$ 11.6 billion by 2030 and is predicted to grow at a CAGR of 10.6% from 2021 to 2030.

According to Vision Research Reports, the Orthobiologics market size is expected to hit around US$ 20.2 billion by 2030 and is predicted to grow at a CAGR of 17.5% from 2021 to 2030.

PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that its partner, the Institute for Molecular Medicine (IMM) was awarded a $12 million grant from the National Institute on Aging (NIA) division of the National Institutes of Health (NIH).

Increasing incidence of chronic and acute diseases across the globe, rising geriatric population, and high usage of smart wearable medical devices are some key factors expected to drive global market growth

Paradigm Biopharmaceuticals Ltd (ASX: PAR) (“Paradigm” or “the Company”), is honored that its Global Clinical Head of Osteoarthritis (OA) Mukesh Ahuja was selected to speak at the Biological Association 3rd Annual Summit, held in conjunction with the 2022 Arthroscopy Association of North America (AANA) Annual Meeting, in San Francisco.

Sysmex Inostics has expanded its offering of CLIA-validated tests to include AML-SEQ™, a focused panel to detect mutations of the three most prevalent genes found in Acute Myeloid Leukemia – IDH1/2 & NPM1.

MaaT Pharmam announced that it will host its first R&D Day for analysts and investors to be held virtually on Tuesday, June 7th, 2022 from 4:00 pm CEST to 6:00 pm CEST.

According to Emergen Research, the global spinal surgery devices market size was USD 10.22 billion in 2019 and is expected to reach USD 14.70 billion in 2027 and register a revenue CAGR of 4.6% during the forecast period, 2020-2027.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that results from multiple studies evaluating the efficacy of vonoprazan were presented at Digestive Disease Week® (DDW) 2022, being held May 21-24 in person in San Diego, CA and virtually.

The increasing prevalence of chronic diseases and development of novel techniques is driving the demand for the market.